Idera Pharma nabs new patent in U.S.; shares up 4% premarket

The USPTO will issue on November 5, U.S. Patent No. 10,10,463,686 to Idera Pharmaceuticals (NASDAQ:IDRA), entitled “Immune Modulation With TLR9 Agonists For Cancer Treatment,” which includes Company’s investigational therapy tilsotolimod (IMO-2125).

The patent includes 24 claims directed to methods of treating melanoma with intratumoral administration of tilsotolimod in combination with certain immune checkpoint inhibitor therapies including CTLA-4, PD-1 or PD-L1 proteins. The patent provides exclusivity through September 2037.

Shares are up 4% premarket.

https://seekingalpha.com/news/3507201-idera-pharma-nabs-new-patent-u-s-shares-4-percent-premarket